Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unrese...
Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN ( Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland )
27 Sep 2022
Intraoperative Radiotherapy
Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal
Intraoperative Radiotherapy ( Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal )
25 Sep 2022
Cancer survivors' stories: An African perspective
Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation
Cancer survivors' stories: An African perspective ( Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation )
15 Sep 2022
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-li...
Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC ( Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia )
14 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
A new era of early cancer detection with blood test may change cancer screening ...
Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA
A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )
11 Sep 2022
Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanc...
Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium
Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )
11 Sep 2022
Pembro + CRT in HNSCC fails to deliver statistically significant event-free surv...
Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium
Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )
11 Sep 2022
New era of early cancer detection blood tests on the horizon
Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA
New era of early cancer detection blood tests on the horizon ( Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA )
11 Sep 2022
Prognostic model of all-cause mortality at 30 days in patients with cancer and C...
Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA
Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19 ( Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA )
11 Sep 2022
New data presented at ESMO for multi-cancer early detection
Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences
New data presented at ESMO for multi-cancer early detection ( Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences )
10 Sep 2022
Working to improve global cancer care access in low middle-income countries
Dr Julie Gralow, Prof Eduardo Cazap
Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )
25 Jul 2022